Mode
Text Size
Log in / Sign up

Mepitel Film showed no difference versus StrataXRT for moist desquamation in breast cancer patients receiving adjuvant radiation therapy.

Mepitel Film showed no difference versus StrataXRT for moist desquamation in breast cancer patients …
Photo by CDC / Unsplash
Key Takeaway
Note that Mepitel Film reduced severe radiation dermatitis but showed no difference in moist desquamation versus StrataXRT in this meta-analysis.

This systematic review and meta-analysis pooled data from randomized controlled trials involving 120 breast cancer patients receiving adjuvant radiation therapy. The study compared the use of Mepitel Film against StrataXRT to assess skin toxicity outcomes during post-mastectomy radiotherapy. Methodological limitations included small and potentially underpowered sample sizes, as well as variations in radiation fractionation schedules and radiotherapy techniques.

Regarding primary outcomes, the incidence of moist desquamation was similar between groups, with a relative risk of 1.03 (95% CI 0.52-2.04; P = 0.93). Specifically, 21.7% of patients in the StrataXRT group experienced moist desquamation compared to 20.0% in the Mepitel Film group. For Grade 2 or 3 radiation dermatitis, Mepitel Film demonstrated a significant reduction in incidence with a relative risk of 1.34 (95% CI 1.10-1.64; P = 0.004).

Safety and tolerability data were mixed. While no serious adverse events or discontinuations were reported, itchiness was noted as an adverse event. The incidence of itchiness was 10.8% with Mepitel Film versus 5.0% with StrataXRT, representing a trend toward higher incidence with Mepitel Film (P = 0.11). Patient preference data regarding the dressings were conflicting. Given the underlying methodological limitations and small sample size, these findings should be interpreted with caution before altering clinical practice.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Radiation dermatitis (RD) affects up to 90% of patients receiving post-mastectomy radiotherapy, with moist desquamation causing significant morbidity. Barrier films and dressings such as Mepitel Film and StrataXRT have been shown to be effective compared to moisturizers, but their relative effectiveness remains debated. This systematic review and meta-analysis compares these interventions for preventing RD. METHODS: Following PRISMA guidelines, we systematically searched MEDLINE, Embase, and Cochrane Library through March 14, 2026. An additional grey literature search was performed in clinicaltrials.gov and Google Scholar. Eligible studies were RCTs directly comparing StrataXRT and Mepitel Film in breast cancer patients receiving adjuvant radiation therapy. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2.0 and certainty of evidence with the GRADE appraoch. Meta-analysis used random-effects models to pool risk ratios (RR) for moist desquamation, and incidence of grade 2 and 3 RD, with I statistics quantifying heterogeneity. RESULTS: From 33 screened records, two intra-patient, non-inferiority RCTs (n = 120) met inclusion criteria. Both studies randomized medial/lateral chest wall halves to each intervention in post-mastectomy patients. Pooled analysis revealed no significant difference in moist desquamation incidence between StrataXRT (21.7%) and Mepitel Film (20.0%) (RR 1.03; 95% CI 0.52-2.04; P = 0.93), with low heterogeneity (I = 35%). Secondary outcomes showed Mepitel Film significantly reduced grade 2 or 3 RD (RR 1.34, 95% CI 1.10-1.64, P = 0.004). However, Mepitel Film trended toward higher incidence of itchiness (10.8% vs. 5.0%, P = 0.11). Patient preference data were conflicting, with one trial favoring StrataXRT for ease of use and the other showing no clear preference. CONCLUSION: While StrataXRT and Mepitel Film demonstrated similar efficacy for preventing moist desquamation, Mepitel Film offered superior protection against grade 2 to 3 RD. However, this conclusion should be interpreted with caution given the underlying methodological limitations of the included studies, including small and potentially underpowered sample sizes, and variations in radiation fractionation schedules and RT techniques.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.